Key facts
- It has raised $56.1M across 1 recorded rounds; the latest was Later Stage VC ($52.6M) in Oct 2021.
- Notable investors include Venrock, HBM Partners, ArrowMark Partners, Mitsui Global Investment, California Institute for Regenerative Medicine — 9 tracked in total.
- Mahzi Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Jul 2024 ($52.6M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Mahzi Therapeutics
Funding rounds
1 roundsAbout Mahzi Therapeutics
Operator of a therapeutics development firm intended to offer underserved rare genetic neurodevelopmental disorders. The company focuses on the research, development, and manufacturing of biopharmaceuticals and provides molecular therapeutics, enabling healthcare clients to treat rare neuroregenerative diseases efficiently.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2020
- Employees
- 21
- Website
- mahzi.com/
- Ownership
- Privately Held (backing)
Mahzi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mahzi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mahzi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.